WO2022219567A1 - Nano-particulated naproxen composition in vegetable oil useful for the treatment of inflammation and pain - Google Patents

Nano-particulated naproxen composition in vegetable oil useful for the treatment of inflammation and pain Download PDF

Info

Publication number
WO2022219567A1
WO2022219567A1 PCT/IB2022/053490 IB2022053490W WO2022219567A1 WO 2022219567 A1 WO2022219567 A1 WO 2022219567A1 IB 2022053490 W IB2022053490 W IB 2022053490W WO 2022219567 A1 WO2022219567 A1 WO 2022219567A1
Authority
WO
WIPO (PCT)
Prior art keywords
oil
naproxen
pain
composition
composition according
Prior art date
Application number
PCT/IB2022/053490
Other languages
Spanish (es)
French (fr)
Inventor
Oscar Alzate
Original Assignee
Oscar Alzate
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oscar Alzate filed Critical Oscar Alzate
Publication of WO2022219567A1 publication Critical patent/WO2022219567A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

  • the development belongs to the chemical, pharmaceutical and medicine fields in general, particularly to a topical composition of nano-particulate naproxen in an oily vehicle, useful as an analgesic and anti-inflammatory agent.
  • Non-steroidal anti-inflammatory drugs constitute a family of mainly anti-inflammatory, analgesic and antipyretic compounds, which treat symptoms such as inflammation, pain and fever.
  • NSAIDs are widely consumed among the world's population as over-the-counter and prescription drugs, where the problem with this growing trend lies in the presence of side effects, such as gastrointestinal effects associated with their use.
  • mode of action as inhibitors of the activity of the enzyme cyclooxygenase (COX) that mediates the biosynthesis of prostaglandins, thromboxane and prostacyclins, while certain classes of prostaglandins have the property of protecting the gastrointestinal epithelium from a series of ulcerogenic conditions, therefore when blocked, the cytoprotective nature of these lipid mediators is also affected.
  • COX cyclooxygenase
  • patent US9351984 discloses a pharmaceutical composition comprising NSAIDs that are added directly to an oil containing phospholipids, such as lecithin or a bio-compatible oil to which a phospholipid has been added, to prepare a composition with low gastrointestinal toxicity and enhanced therapeutic activity to treat or prevent inflammation, pain, fever, platelet aggregation, tissue ulceration, and/or other tissue disorders.
  • an oil containing phospholipids such as lecithin or a bio-compatible oil to which a phospholipid has been added
  • compositions are in the form of a non-aqueous solution, paste, suspension, dispersion, colloidal suspension or in the form of an aqueous emulsion or microemulsion for internal, oral, direct or topical administration.
  • the compositions may be in the form of an ointment, paste, oil, emulsion, microemulsion, or mixtures or combinations thereof.
  • the compositions can be mixed with other ingredients commonly used in ointments and in the cosmetic industry.
  • patent US20110033545 discloses topical pharmaceutical preparations that comprise both a solution and a suspension of nanoparticles and methods for the treatment of acute and chronic pain that use said preparations.
  • the disclosed preparations comprise a therapeutically effective amount of a nano-sized NSAID drug and a pharmaceutically acceptable carrier suitable for topical administration.
  • the nonsteroidal anti-inflammatory drug is presented in the form of nanoparticles of less than 1000 nm, preferably 40 to 60 nm.
  • Pharmaceutical preparations are intended to be administered topically by any known means; for example, creams, gels, lotions, ointments and transdermal patches.
  • the administration of the pharmaceutical preparations must be local, so as to minimize, as much as possible, the undesired collateral effects that may arise with systemic administration.
  • authors such as Gaber D. [Gaber D. (2019). Nano-lipid particles of naproxen for topical application: In vitro / in vivo study.
  • lipid nanoparticle-based (NpxNps)-based naproxen gel formulations for the treatment of osteoarthritis.
  • This study evaluates the characterization of the NpxNps for application topical by its physical characteristics, as well as in vivo transdermal release and analgesic effect.
  • the average size of the particles is in the range between 203 ⁇ 10 nm and 228 ⁇ 30 nm, so the author mentions that lipid-based nanoparticles with a pattern of controlled drug release can be a useful technology to improve drug release.
  • naproxen through a transdermal delivery system since they have the advantage of being nanometric in size and lipophilic in nature. Additionally, they are considered a safe vehicle for drugs since they are composed of biocompatible and biodegradable components.
  • the present development refers to a topical composition comprising nano-particulate naproxen as an active ingredient arranged in an oily vehicle selected from one or more oils rich in terpenoids and pharmaceutically acceptable excipients. Additionally, the present development also refers to the method for preparing said compositions. In an additional aspect, the present development refers to the use of the nano-particulate naproxen composition as an anti-inflammatory and/or analgesic agent, for the treatment of diseases or conditions associated with inflammation and/or joint or muscle pain, rheumatoid arthritis , osteoarthritis, back pain, chronic pain, muscle pain, muscle pain associated with menstruation, tendonitis, dental pain, and bursitis, among others.
  • the present development corresponds to a topical composition of nanoparticulate naproxen as active ingredient, an oily vehicle that is selected from one or more oils rich in terpenoids and pharmaceutically acceptable excipients.
  • Nanoparticulate naproxen is understood as naproxen nanoparticles that have particle sizes that do not exceed 800 nm.
  • the naproxen nanoparticles have sizes between 200 and 500 nm and in another particular embodiment between 200 and 300 nm.
  • the concentration of nano-particulate naproxen is up to 20% by weight, between 0.5 and 15% by weight or between 7.5 and 10% by weight.
  • nano-particulate naproxen By incorporating the nano-particulate naproxen into the oily vehicle, unique structures such as micelles or vesicles are formed that allow the active ingredient to be transported through the skin.
  • this is a natural property of terpenoids, since its oily nature allows it to maintain the micelles or vesicles that encapsulate the nano-particulate naproxen and give it the ability to permeate the layers of the skin, releasing itself at the site of action.
  • the oils comprise terpenoid-rich eucalyptus oil, aromatic and flavonoid-rich cedar oil, and astragalin-rich moringa oil.
  • the pharmaceutically acceptable excipients can be of the hydrophilic or lipophilic type, such as diluents, solvents, lubricants, colorants, flavoring agents, antioxidants, stabilizers, thickeners, humectants, and antimicrobial agents.
  • excipients are incorporated into the composition to reduce the effects of environmental conditions on the stability of the active ingredient.
  • the excipients have aromatic properties that produce relaxing effects through aromatherapy.
  • the present development is also directed to the method of making a nano-particulate naproxen composition.
  • the preparation method of the composition comprises obtaining nanoparticles of naproxen, mixing the nanoparticles with one or more vegetable oils rich in terpenoids and adding pharmaceutically acceptable excipients, where an additional component selected from flavonoids of vegetable origin with beneficial properties can also be incorporated. anti-inflammatory, antioxidant, and/or antibacterial.
  • the size of the nanoparticles is determined using techniques known in the art, such as light scattering, Raman diffraction, microscopy, or atomic testing.
  • a vegetable oil rich in terpenoids is added, selected from, without limitation, moringa oil, eucalyptus oil, tea oil, sage oil, citrus tree oil, pine oil, of cedar, lavender oil, menthol oil, and/or camphor oil, at room temperature (23 °C), with constant low revolution stirring (approximately 30 to 50 rpm), in a proportion of 3 to 5 volumes of the oil to 1 volume of the nano-particulate, until a homogeneous mixture is obtained.
  • terpenoids and/or flavonoids are optionally added under the same conditions, selected from, but not limited to, quercetin, isoquercetin, chlorogenic acid, astragalin, or mixtures thereof.
  • the composition obtained in the present invention is useful as an analgesic and/or anti-inflammatory agent and in general for purposes of treating, curing, and/or rehabilitating a condition or disease associated with inflammation and/or pain, alone or as a complement to treatments. conventional in situations of intense pain.
  • the inflammation and/or pain is of a joint or muscular type, more preferably rheumatoid arthritis, osteoarthritis, back pain, chronic pain, muscular pain, muscular pain associated with menstruation, tendinitis, dental pain and bursitis.
  • the application of the composition on the skin guarantees a prolonged effect, which suggests that the composition of the present invention is suitable for the treatment of chronic pain.
  • Example 1 Composition of nano-particulate naproxen transported in a mixture of vegetable oils
  • composition C a moringa extract was prepared by heating the moringa leaf extract powder to boiling in water with 10% glycerin, followed by resuspension in various percentages of organics/water, and removal of the organics by consecutive washes in water.
  • the extracts were filtered through Whatman No. 10 filter paper, followed by drying at room temperature and dispersing this precipitate in 2.0 mL of mineral oil.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to a topical composition comprising nano-particulated naproxen as the active ingredient, arranged on an oily vehicle which is selected from one or more terpenoid-rich oil and pharmaceutically acceptable excipients. The present invention also relates to the method of producing said composition through the steps of obtaining naproxen nanoparticles having a particle size between 200 and 300 nm, mixing the nanoparticles with one or more terpenoid-rich vegetable oils, adding pharmaceutically acceptable excipients and optionally additional compounds such as quercetin, isoquercetin, chlorogenic acid, astragalin or mixtures thereof until a homogeneous mixture is obtained. The composition developed enables the naproxen to be transported such that it is effectively absorbed through the skin, favouring the analgesic and/or anti-inflammatory effect of the naproxen, guaranteeing the delivery of the active ingredient to the site of action, decreasing the time of action due to its application and local action and decreasing or eliminating the gastric side effects of the action mechanism of the active ingredient compared to commercially known compositions.

Description

COMPOSICIÓN DE NAPROXENO NANO-PARTICULADO EN ACEITE VEGETAL ÚTIL PARA EL TRATAMIENTO DE LA INFLAMACIÓN Y EL COMPOSITION OF NANO-PARTICULATED NAPROXEN IN VEGETABLE OIL USEFUL FOR THE TREATMENT OF INFLAMMATION AND
DOLOR PAIN
CAMPO DE LA INVENCIÓN FIELD OF THE INVENTION
El desarrollo pertenece al campo químico, farmacéutico y de medicina en general, particularmente a una composición tópica de naproxeno nano-particulado en un vehículo oleoso, útil como agente analgésico y antinflamatorio. The development belongs to the chemical, pharmaceutical and medicine fields in general, particularly to a topical composition of nano-particulate naproxen in an oily vehicle, useful as an analgesic and anti-inflammatory agent.
DESCRIPCIÓN DEL ESTADO DE LA TÉCNICA DESCRIPTION OF THE STATE OF THE ART
Los medicamentos antinflamatorios no esteroideos (AINE) constituyen una familia de compuestos principalmente antinflamatorios, analgésicos y antipiréticos, que permiten tratar síntomas como la inflamación, el dolor y la fiebre. Non-steroidal anti-inflammatory drugs (NSAIDs) constitute a family of mainly anti-inflammatory, analgesic and antipyretic compounds, which treat symptoms such as inflammation, pain and fever.
Debido a su gran potencial terapéutico, los AINE se consumen en gran medida entre la población mundial como medicamentos de venta libre y recetados, en donde el problema con esta creciente tendencia radica en la presencia de efectos secundarios, tales como los efectos gastrointestinales asociados a su modo de acción como inhibidores de la actividad de la enzima ciclooxigenasa (COX) que media la biosíntesis de prostaglandinas, tromboxano y prostaciclinas, en tanto ciertas clases de prostaglandinas tienen la propiedad de proteger al epitelio gastrointestinal de una serie de afecciones ulcerogénicas, por lo que al ser bloqueadas, la naturaleza citoprotectora de estos mediadores lipidíeos se ve igualmente afectada. Due to their great therapeutic potential, NSAIDs are widely consumed among the world's population as over-the-counter and prescription drugs, where the problem with this growing trend lies in the presence of side effects, such as gastrointestinal effects associated with their use. mode of action as inhibitors of the activity of the enzyme cyclooxygenase (COX) that mediates the biosynthesis of prostaglandins, thromboxane and prostacyclins, while certain classes of prostaglandins have the property of protecting the gastrointestinal epithelium from a series of ulcerogenic conditions, therefore when blocked, the cytoprotective nature of these lipid mediators is also affected.
Por lo tanto, en aras de evitar los efectos gastrointestinales asociados a la administración oral de los AINE, se han desarrollado preparaciones farmacéuticas tópicas que puedan ejercer su acción localizada y así mismo evitar otros efectos secundarios no deseados que pueden surgir tras la administración sistémica del fármaco. Particularmente, la patente US9351984 divulga una composición farmacéutica que comprende AINEs que se adicionan directamente a un aceite que contiene fosfolípidos, tal como lecitina o un aceite bio-compatible al que se le ha agregado un fosfolípido, para preparar una composición de baja toxicidad gastrointestinal y actividad terapéutica mejorada para tratar o prevenir la inflamación, el dolor, la fiebre, la agregación plaquetaria, la ulceración de tejidos y/u otros desórdenes tisulares. La composición está en forma de una solución no acuosa, pasta, suspensión, dispersión, suspensión coloidal o en forma de una emulsión acuosa o microemulsión para administración intema, oral, directa o tópica. Para administración tópica, las composiciones pueden estar en forma de ungüento, pasta, aceite, emulsión, microemulsión o mezclas o combinaciones de las mismas. Más aun, las composiciones pueden estar mezcladas con otros ingredientes comúnmente usados en ungüentos y en la industria cosmética. Therefore, in order to avoid the gastrointestinal effects associated with the oral administration of NSAIDs, topical pharmaceutical preparations have been developed that can exert their localized action and also avoid other unwanted side effects that may arise after systemic administration of the drug. . In particular, patent US9351984 discloses a pharmaceutical composition comprising NSAIDs that are added directly to an oil containing phospholipids, such as lecithin or a bio-compatible oil to which a phospholipid has been added, to prepare a composition with low gastrointestinal toxicity and enhanced therapeutic activity to treat or prevent inflammation, pain, fever, platelet aggregation, tissue ulceration, and/or other tissue disorders. The composition is in the form of a non-aqueous solution, paste, suspension, dispersion, colloidal suspension or in the form of an aqueous emulsion or microemulsion for internal, oral, direct or topical administration. For topical administration, the compositions may be in the form of an ointment, paste, oil, emulsion, microemulsion, or mixtures or combinations thereof. Furthermore, the compositions can be mixed with other ingredients commonly used in ointments and in the cosmetic industry.
Por otro lado, la patente US20110033545 divulga preparaciones farmacéuticas tópicas que comprenden tanto una solución como una suspensión de nanopartículas y métodos para el tratamiento del dolor agudo y crónico que emplean dichas preparaciones. On the other hand, patent US20110033545 discloses topical pharmaceutical preparations that comprise both a solution and a suspension of nanoparticles and methods for the treatment of acute and chronic pain that use said preparations.
Las preparaciones divulgadas, comprenden una cantidad terapéuticamente efectiva de un fármaco AINE de tamaño nanométrico y un portador farmacéuticamente aceptable, apropiado para su administración tópica. En la segunda presentación, el fármaco antinflamatorio no esteroide se presenta en forma de nanopartículas de menos de 1000 nm, preferiblemente de 40 a 60 nm. Las preparaciones farmacéuticas tienen el propósito de ser administradas tópicamente por cualquier medio conocido; por ejemplo, cremas, geles, lociones, ungüentos y parches transdérmicos. La administración de las preparaciones farmacéuticas debe ser local, de manera que se minimicen, en lo posible, los efectos colaterales indeseados que pueden surgir con la administración sistémica. finalmente, autores como Gaber D. [Gaber D. (2019). Nano-lipid partióles of naproxen for topical application: In vitro / in vivo study. Journal of Innovations in Pharmaceutical and Biological Sciences (JIPBS), 6(1), 31-36] enseñan formulaciones en gel de naproxeno basadas en nanopartículas lipídicas (NpxNps) para el tratamiento de la osteoartritis. En este estudio se evalúa la caracterización de las NpxNps para aplicación tópica mediante sus características físicas, así como la liberación transdérmica in vivo y el efecto analgésico. El tamaño medio de las partículas está en el rango entre 203 ± 10 nm y 228 ± 30 nm, por lo que el autor menciona que las nanopartículas basadas en lípidos con un patrón de liberación controlada de fármacos pueden ser una tecnología útil para mejorar la liberación de naproxeno a través de un sistema de liberación transdérmico ya que tienen la ventaja de tener un tamaño nanométrico y una naturaleza lipofílica. Adicionalmente se consideran un vehículo seguro para fármacos dado que están compuestas de componentes biocompatibles y biodegradables. The disclosed preparations comprise a therapeutically effective amount of a nano-sized NSAID drug and a pharmaceutically acceptable carrier suitable for topical administration. In the second presentation, the nonsteroidal anti-inflammatory drug is presented in the form of nanoparticles of less than 1000 nm, preferably 40 to 60 nm. Pharmaceutical preparations are intended to be administered topically by any known means; for example, creams, gels, lotions, ointments and transdermal patches. The administration of the pharmaceutical preparations must be local, so as to minimize, as much as possible, the undesired collateral effects that may arise with systemic administration. finally, authors such as Gaber D. [Gaber D. (2019). Nano-lipid particles of naproxen for topical application: In vitro / in vivo study. Journal of Innovations in Pharmaceutical and Biological Sciences (JIPBS), 6(1), 31-36] teach lipid nanoparticle-based (NpxNps)-based naproxen gel formulations for the treatment of osteoarthritis. This study evaluates the characterization of the NpxNps for application topical by its physical characteristics, as well as in vivo transdermal release and analgesic effect. The average size of the particles is in the range between 203 ± 10 nm and 228 ± 30 nm, so the author mentions that lipid-based nanoparticles with a pattern of controlled drug release can be a useful technology to improve drug release. of naproxen through a transdermal delivery system since they have the advantage of being nanometric in size and lipophilic in nature. Additionally, they are considered a safe vehicle for drugs since they are composed of biocompatible and biodegradable components.
Sin embargo, estas formulaciones presentan limitaciones como por ejemplo que las nanopartículas de lípidos carecen de la estabilidad suficiente para permanecer en la piel durante el tiempo necesario para que el ingrediente activo se absorba a través de la piel y alcance el sitio de acción; las combinaciones de ingredientes activos nano particulados no necesariamente conservan su conformación al ser mezclados por lo que requieren la adición de adyuvantes farmacéuticos para proveer estabilidad y eficiencia, además que se debe demostrar que estas mezclas no resultan en nuevos compuestos con propiedades fisicoquímicas diferentes a los componentes individuales. However, these formulations have limitations such as, for example, that the lipid nanoparticles lack sufficient stability to remain on the skin for the time necessary for the active ingredient to be absorbed through the skin and reach the site of action; combinations of nanoparticulate active ingredients do not necessarily retain their shape when mixed, so they require the addition of pharmaceutical adjuvants to provide stability and efficiency, and it must also be demonstrated that these mixtures do not result in new compounds with physicochemical properties different from those of the components. individual.
Por lo tanto, aún persiste la necesidad de desarrollar formulaciones tópicas estables de AINE que permitan la acción localizada en el sitio del dolor y/o la inflamación, reduciendo los efectos secundarios y los tiempos de acción asociados al consumo oral y la distribución sistémica. Therefore, there is still a need to develop stable topical formulations of NSAIDs that allow localized action at the site of pain and/or inflammation, reducing side effects and action times associated with oral consumption and systemic distribution.
BREVE DESCRIPCIÓN DE LA INVENCIÓN BRIEF DESCRIPTION OF THE INVENTION
El presente desarrollo hace referencia a una composición tópica que comprende naproxeno nano-particulado como ingrediente activo dispuesto en un vehículo oleoso que se selecciona entre uno o más aceites ricos en terpenoides y excipientes farmacéuticamente aceptables. Adicionalmente, el presente desarrollo también hace referencia al método para elaborar dichas composiciones. En un aspecto adicional, el presente desarrollo hace referencia al uso de la composición de naproxeno nano-particulado como agente antinflamatorio y/o analgésico, para el tratamiento de enfermedades o condiciones asociadas con la inflamación y/o el dolor articular o muscular, artritis reumatoide, osteoartritis, dolor de espalda, dolores crónicos, dolores musculares, dolores musculares asociados con la menstruación, tendinitis, dolor dental, y bursitis, entre otros. The present development refers to a topical composition comprising nano-particulate naproxen as an active ingredient arranged in an oily vehicle selected from one or more oils rich in terpenoids and pharmaceutically acceptable excipients. Additionally, the present development also refers to the method for preparing said compositions. In an additional aspect, the present development refers to the use of the nano-particulate naproxen composition as an anti-inflammatory and/or analgesic agent, for the treatment of diseases or conditions associated with inflammation and/or joint or muscle pain, rheumatoid arthritis , osteoarthritis, back pain, chronic pain, muscle pain, muscle pain associated with menstruation, tendonitis, dental pain, and bursitis, among others.
DESCRIPCIÓN DETALLADA DE LA INVENCIÓN DETAILED DESCRIPTION OF THE INVENTION
Para propósitos de interpretar los términos usados a lo largo del presente documento se debe tener en cuenta su significado usual en el campo técnico, a menos que se incorpore una definición particular o el contexto indique claramente lo contrario. Adicionalmente, los términos utilizados en forma singular también incluirán la forma plural. For purposes of interpreting the terms used throughout this document, their usual meaning in the technical field should be taken into account, unless a particular definition is incorporated or the context clearly indicates otherwise. Additionally, terms used in the singular form will also include the plural form.
Composición Composition
El presente desarrollo corresponde a una composición tópica de naproxeno nano- particulado como ingrediente activo, un vehículo oleoso que se selecciona de uno o más aceites ricos en terpenoides y excipientes farmacéuticamente aceptables. The present development corresponds to a topical composition of nanoparticulate naproxen as active ingredient, an oily vehicle that is selected from one or more oils rich in terpenoids and pharmaceutically acceptable excipients.
Se entiende por naproxeno nano-particulado a las nano partículas de naproxeno que tienen tamaños de partícula que no superan los 800 nm. En una modalidad particular las nano partículas de naproxeno son de tamaños entre los 200 y 500 nm y en otra modalidad particular entre los 200 y 300 nm. Nanoparticulate naproxen is understood as naproxen nanoparticles that have particle sizes that do not exceed 800 nm. In a particular embodiment, the naproxen nanoparticles have sizes between 200 and 500 nm and in another particular embodiment between 200 and 300 nm.
El tamaño de partícula del naproxeno incide directamente sobre la efectividad del naproxeno ya que una formulación homogénea nano particulada presenta una mejor penetración en la piel, un período extendido para la liberación del componente activo debido al tamaño reducido y al aumento en el área superficial de la nano partícula. Adicionalmente, al tener una mayor área superficial es posible usar menores cantidades lo que lo hace más seguro mientras se mantiene la efectividad. La composición de la presente invención comprende concentraciones de naproxeno menores a las que se usan en formulaciones orales, que se encuentran alrededor de 250 mg, mientras que se obtienen resultados equivalentes con una cantidad por lo menos 25 veces menor y sin los riesgos asociados con la distribución sistémica y el uso prolongado del compuesto, que se han descrito, tales como riesgos aumentados de ataque cardiaco o derrame cerebral. The particle size of naproxen directly affects the effectiveness of naproxen since a homogeneous nanoparticulate formulation presents better penetration into the skin, an extended period for the release of the active component due to the reduced size and the increase in the surface area of the nanoparticle. Additionally, by having a higher surface area it is possible to use smaller amounts which makes it safer while maintaining effectiveness. The composition of the present invention comprises lower concentrations of naproxen than those used in oral formulations, which are around 250 mg, while equivalent results are obtained with an amount at least 25 times lower and without the risks associated with systemic distribution and prolonged use of the compound, which have been described, such as increased risks of heart attack or stroke.
En una modalidad particular, la concentración de naproxeno nano-particulado es de hasta 20% en peso, de entre 0,5 y 15% en peso o de entre 7,5 y 10% en peso. In a particular embodiment, the concentration of nano-particulate naproxen is up to 20% by weight, between 0.5 and 15% by weight or between 7.5 and 10% by weight.
El vehículo oleoso para efectos de la presente invención se entiende como uno o más aceites de origen vegetal rico en terpenoides o isoprenoides, es decir con un contenido de al menos el 75% de mono terpenoides tales como eucaliptol. Particularmente un aceite extraído de plantas cuyas flores, hojas o frutos permiten la obtención de aceites esenciales ricos en estos compuestos. En una modalidad particular, sin constituir una limitante el aceite rico en terpenoides se selecciona entre aceite de moringa, de eucalipto, de té, de salvia, de árboles cítricos como limón, pino, lavanda, mentol, alcanfor, o mezclas de los mismos, más preferiblemente el aceite de origen vegetal rico en terpenoides es aceite de eucalipto, moringa, alcanfor o mezclas de los mismos. The oily vehicle for purposes of the present invention is understood as one or more oils of plant origin rich in terpenoids or isoprenoids, that is, with a content of at least 75% of mono terpenoids such as eucalyptol. Particularly an oil extracted from plants whose flowers, leaves or fruits allow the obtaining of essential oils rich in these compounds. In a particular embodiment, without being a limitation, the oil rich in terpenoids is selected from oils of moringa, eucalyptus, tea, sage, citrus trees such as lemon, pine, lavender, menthol, camphor, or mixtures thereof, more preferably the oil of plant origin rich in terpenoids is oil of eucalyptus, moringa, camphor or mixtures thereof.
Al incorporar el naproxeno nano-particulado en el vehículo oleoso se forman estructuras únicas tales como micelas o vesículas que permiten transportar el ingrediente activo a través de la piel. En particular esta es una propiedad natural de los terpenoides, ya que su naturaleza oleosa permite mantener las micelas o vesículas que encapsulan el naproxeno nano-particulado y le confieren la capacidad de permear las capas de la piel liberándose en el sitio de acción. By incorporating the nano-particulate naproxen into the oily vehicle, unique structures such as micelles or vesicles are formed that allow the active ingredient to be transported through the skin. In particular, this is a natural property of terpenoids, since its oily nature allows it to maintain the micelles or vesicles that encapsulate the nano-particulate naproxen and give it the ability to permeate the layers of the skin, releasing itself at the site of action.
En una modalidad particular los aceites comprenden aceite de eucalipto rico en terpenoides, aceite de cedro rico en flavonoides y aromáticos y aceite de moringa rico en astragalina. De acuerdo con el presente desarrollo, los excipientes farmacéuticamente aceptables pueden ser de tipo hidrofílico o lipofílico, tales como diluyentes, solventes, lubricantes, colorantes, aromatizantes, antioxidantes, estabilizantes, espesantes, humectantes, y agentes antimicrobianos. En una modalidad particular el excipiente farmacéuticamente aceptable se selecciona del grupo que consiste en petrolato, aceite de tomillo, aceite de cedro, aceite de limón, aceite de alcanfor, parafina blanda blanca, polioxilglicéridos de caprilocaproilo, aceite de coco, base de dietileno, éter de monoetilenglicol, lanolina, lanolina hidrogenada, alcoholes de lanolina, polioxiglicéridos de lauroilo, polioxiglicéridos de linoleolilo, petrolato hidrofílico, petrolato blanco, polideceno hidrogenado, polietilenglicol, polietilenglicol 3350, polietilenglicol monometil éter, poligliceril-3 diisoestearato, succinato de polietilenglicol y vitamina E. In a particular embodiment, the oils comprise terpenoid-rich eucalyptus oil, aromatic and flavonoid-rich cedar oil, and astragalin-rich moringa oil. According to the present development, the pharmaceutically acceptable excipients can be of the hydrophilic or lipophilic type, such as diluents, solvents, lubricants, colorants, flavoring agents, antioxidants, stabilizers, thickeners, humectants, and antimicrobial agents. In a particular embodiment, the pharmaceutically acceptable excipient is selected from the group consisting of petrolatum, thyme oil, cedarwood oil, lemon oil, camphor oil, white soft paraffin, caprylocaproyl polyoxylglycerides, coconut oil, diethylene base, ether monoethylene glycol, lanolin, hydrogenated lanolin, lanolin alcohols, polyoxyglycerides lauroyl, polyoxyglycerides linoleolyl, hydrophilic petrolatum, white petrolatum, hydrogenated polydecene, polyethylene glycol, polyethylene glycol 3350, polyethylene glycol monomethyl ether, polyglyceryl-3 diisostearate, polyethylene glycol succinate, and vitamin E.
En una modalidad particular, los excipientes se incorporan en la composición para disminuir los efectos de las condiciones ambientales sobre la estabilidad del ingrediente activo. En otra modalidad particular los excipientes tienen propiedades aromáticas que producen efectos relajantes a través de la aromaterapia. In a particular embodiment, excipients are incorporated into the composition to reduce the effects of environmental conditions on the stability of the active ingredient. In another particular modality, the excipients have aromatic properties that produce relaxing effects through aromatherapy.
En una modalidad particular se emplea petrolato como excipiente. En otra modalidad particular los excipientes comprenden aceites esenciales. In a particular embodiment, petrolatum is used as an excipient. In another particular embodiment, the excipients comprise essential oils.
Adicionalmente, y sin constituir una limitante la composición puede comprender flavonoides de origen vegetal con propiedades antinflamatorias, antioxidantes, y/o antibacteriales. En una modalidad particular, el componente adicional es quercetina, isoquercetina, ácido clorogénico, astragalina o mezclas de los mismos. En una modalidad particular, los elementos adicionales son polifenoles que se extraen de la Moringa oleífera o están contenidos en el extracto de Moringa oleífera. Additionally, and without being limiting, the composition may comprise plant-derived flavonoids with anti-inflammatory, antioxidant, and/or antibacterial properties. In a particular embodiment, the additional component is quercetin, isoquercetin, chlorogenic acid, astragalin, or mixtures thereof. In a particular embodiment, the additional elements are polyphenols that are extracted from Moringa oleifera or are contained in the Moringa oleifera extract.
En una modalidad particular el componente adicional o mezclas de los mismos está en una concentración de hasta 20% en peso. En otra modalidad particular la composición comprende los componentes adicionales en una concentración de entre 0,1 y 15%enpeso. La bibliografía reporta el contenido de compuestos polifenólicos en extractos de hoja de Moringa oleífera, a partir de lo cual es posible calcular el contenido aproximado de cada uno de los componentes adicionales de la composición. Por ejemplo, autores como Vongsak B., et al encontraron que en extractos secos de hojas de moringa, la recuperación vía HPLC es de 98,5% para ácido clorogénico, 98,47% para isoquercetina y 98,59% para astragalina con una precisión de ± 2,0%. El contenido w/w de estos compuestos por gramo de extracto de hoja seca de Moringa oleífera fue determinado como 0,081, 0,120, y 0,153% respectivamente [Vongsak B., et al., (2014). Simultaneous HPLC quantitative analysis of active compounds in leaves of Moringa oleífera Lam. Journal of Chromatographic Science, 52(7): 641-5. URL: https://doi.Org/10.1093/chromsci/bmt0931. In a particular embodiment, the additional component or mixtures thereof is in a concentration of up to 20% by weight. In another particular embodiment, the composition comprises the additional components in a concentration of between 0.1 and 15% by weight. The literature reports the content of polyphenolic compounds in Moringa oleifera leaf extracts, from which it is possible to calculate the approximate content of each of the additional components of the composition. For example, authors such as Vongsak B., et al found that in dry extracts of moringa leaves, recovery via HPLC is 98.5% for chlorogenic acid, 98.47% for isoquercetin and 98.59% for astragalin with a accuracy of ± 2.0%. The w/w content of these compounds per gram of dry leaf extract of Moringa oleifera was determined as 0.081, 0.120, and 0.153%, respectively [Vongsak B., et al., (2014). Simultaneous HPLC quantitative analysis of active compounds in leaves of Moringa oleifera Lam. Journal of Chromatographic Science, 52(7): 641-5. URL: https://doi.org/10.1093/chromsci/bmt0931.
La composición de la presente invención corresponde a una formulación semisólida destinada a ser aplicada sobre la piel con el fin de ejercer acción localizada en forma de ungüento, crema, loción o gel. En una modalidad particular, la composición de la presente invención está en forma de ungüento. The composition of the present invention corresponds to a semi-solid formulation intended to be applied to the skin in order to exert localized action in the form of an ointment, cream, lotion or gel. In a particular embodiment, the composition of the present invention is in the form of an ointment.
Método de elaboración de la composición Method of elaboration of the composition
El presente desarrollo también se dirige al método de elaboración de una composición de naproxeno nano-particulado. El método de elaboración de la composición comprende obtener nano partículas de naproxeno, mezclar las nano partículas con uno o más aceites vegetales ricos en terpenoides y agregar excipientes farmacéuticamente aceptables, en donde adicionalmente se puede incorporar un componente adicional seleccionado de flavonoides de origen vegetal con propiedades antinflamatorias, antioxidantes, y/o antibacteriales. The present development is also directed to the method of making a nano-particulate naproxen composition. The preparation method of the composition comprises obtaining nanoparticles of naproxen, mixing the nanoparticles with one or more vegetable oils rich in terpenoids and adding pharmaceutically acceptable excipients, where an additional component selected from flavonoids of vegetable origin with beneficial properties can also be incorporated. anti-inflammatory, antioxidant, and/or antibacterial.
En la primera etapa se obtienen las nano partículas de naproxeno por cualquier proceso conocido por una persona medianamente versada en la materia; por ejemplo, mediante molienda en un molino Nano Mili de bolas, de cubeta, o de mortero, o una fuente de ultrasonido. En una modalidad particular, el naproxeno sólido se procesa hasta alcanzar un tamaño homogéneo menor o igual a 800 nm, preferiblemente las nano partículas de naproxeno tienen un tamaño entre 200 y 300 nm. In the first stage, the naproxen nanoparticles are obtained by any process known to a person moderately versed in the art; for example, by grinding in a Nano Mill ball, bowl, or mortar mill, or an ultrasonic source. In a particular embodiment, the solid naproxen is processed until it reaches a homogeneous size less than or equal to 800 nm, preferably the naproxen nanoparticles have a size between 200 and 300 nm.
Para propósitos de la presente invención, el tamaño de las nano partículas se determina utilizando técnicas conocidas en el arte, tales como dispersión luminosa, difracción Raman, microscopía, o pruebas atómicas. For purposes of the present invention, the size of the nanoparticles is determined using techniques known in the art, such as light scattering, Raman diffraction, microscopy, or atomic testing.
Una vez alcanzado el tamaño de nano partícula deseado, se adiciona un aceite vegetal rico en terpenoides seleccionado entre, sin limitarse a aceite de moringa, aceite de eucalipto, aceite de té, aceite de salvia, aceite de árboles cítricos, aceite de pino, aceite de cedro, aceite de lavanda, aceite de mentol, y/o aceite de alcanfor, a temperatura ambiente (23 °C), con agitación constante de baja revolución (aproximadamente 30 a 50 rpm), en una proporción de 3 a 5 volúmenes del aceite a 1 volumen del nano-particulado, hasta obtener una mezcla homogénea. Posteriormente, se adicionan opcionalmente otros aceites vegetales ricos en terpenoides y/o flavonoides bajo las mismas condiciones, seleccionados entre, sin limitarse a quercetina, isoquercetina, ácido clorogénico, astragalina o mezclas de los mismos. Once the desired nanoparticle size is reached, a vegetable oil rich in terpenoids is added, selected from, without limitation, moringa oil, eucalyptus oil, tea oil, sage oil, citrus tree oil, pine oil, of cedar, lavender oil, menthol oil, and/or camphor oil, at room temperature (23 °C), with constant low revolution stirring (approximately 30 to 50 rpm), in a proportion of 3 to 5 volumes of the oil to 1 volume of the nano-particulate, until a homogeneous mixture is obtained. Subsequently, other vegetable oils rich in terpenoids and/or flavonoids are optionally added under the same conditions, selected from, but not limited to, quercetin, isoquercetin, chlorogenic acid, astragalin, or mixtures thereof.
Finalmente, se agregan excipientes farmacéuticamente aceptables usando las mismas condiciones. Finally, pharmaceutically acceptable excipients are added using the same conditions.
Usos y métodos de tratamiento Uses and treatment methods
La composición obtenida en la presente invención es útil como agente analgésico y/o antinflamatorio y en general para propósitos de tratar, curar, y/o rehabilitar una condición o enfermedad asociada con inflamación y/o dolor, sola o como un complemento a los tratamientos convencionales en situaciones de dolor intenso. En una modalidad particular, y sin constituir una limitante, la inflamación y/o dolor es de tipo articular o muscular, más preferiblemente artritis reumatoide, osteoartritis, dolor de espalda, dolores crónicos, dolores musculares, dolores musculares asociados con la menstruación, tendinitis, dolor dental y bursitis. La aplicación de la composición en la piel garantiza un efecto prolongado, lo cual sugiere que la composición de la presente invención es adecuada para el tratamiento de dolores crónicos. The composition obtained in the present invention is useful as an analgesic and/or anti-inflammatory agent and in general for purposes of treating, curing, and/or rehabilitating a condition or disease associated with inflammation and/or pain, alone or as a complement to treatments. conventional in situations of intense pain. In a particular modality, and without constituting a limitation, the inflammation and/or pain is of a joint or muscular type, more preferably rheumatoid arthritis, osteoarthritis, back pain, chronic pain, muscular pain, muscular pain associated with menstruation, tendinitis, dental pain and bursitis. The application of the composition on the skin guarantees a prolonged effect, which suggests that the composition of the present invention is suitable for the treatment of chronic pain.
Finalmente, la composición de la invención sirve para el tratamiento de las condiciones anteriormente mencionadas a través de la administración de una cantidad terapéuticamente efectiva de la composición en el sitio del dolor o la inflamación. Una cantidad terapéuticamente efectiva para efectos de la presente invención se define como la cantidad o dosis mínima de la composición que permite producir el efecto deseado a saber, antinflamatorio y/o analgésico determinado de acuerdo con los métodos de la práctica clínica. Finally, the composition of the invention is useful for the treatment of the aforementioned conditions through the administration of a therapeutically effective amount of the composition at the site of pain or inflammation. A therapeutically effective amount for purposes of the present invention is defined as the minimum amount or dose of the composition that allows the desired effect to be produced, namely, anti-inflammatory and/or analgesic determined according to the methods of clinical practice.
La presente invención será presentada en detalle a través de los siguientes ejemplos, los cuales son suministrados solamente con propósitos ilustrativos y no con el objetivo de limitar su alcance. The present invention will be presented in detail through the following examples, which are provided for illustrative purposes only and not for the purpose of limiting its scope.
EJEMPLOS EXAMPLES
Ejemplo 1. Composición de naproxeno nano-particulado vehiculizado en una mezcla de aceites vegetales Example 1. Composition of nano-particulate naproxen transported in a mixture of vegetable oils
Se emplearon los siguientes ingredientes para obtener las composiciones que se ilustran en la Tabla 1 a continuación: The following ingredients were used to obtain the compositions illustrated in Table 1 below:
• naproxeno Sigma-Aldrich (Catalogo N8280) con un tamaño de partícula de aproximadamente 300 nm • Sigma-Aldrich naproxen (Catalog N8280) with a particle size of approximately 300 nm
• aceite de eucalipto (100% puro, NOW Essential Oils) • eucalyptus oil (100% pure, NOW Essential Oils)
• aceite de alcanfor (Sigma, Catalogo 21300) • camphor oil (Sigma, Catalog 21300)
• aceite de menta piperita de Sigma-Aldrich (Catalogo 77411) • Sigma-Aldrich peppermint oil (Catalog 77411)
• aceite de cedro (100% puro, NOW Essential Oils) • cedarwood oil (100% pure, NOW Essential Oils)
• gel de petrolato (White Petrolatum #912558, USP 100%) • petrolatum gel (White Petrolatum #912558, USP 100%)
• extracto de moringa (Polvo de extracto de hoja de moringa oleífera, 100% aprobado por la US FDA, Zen Principie) aceite de limón (100% puro, NOW Essential Oils) • moringa extract (Moringa oleifera leaf extract powder, 100% US FDA approved, Zen Principie) lemon oil (100% pure, NOW Essential Oils)
Tabla 1. Composiciones de naproxeno nano-particulado obtenidas
Figure imgf000011_0001
Table 1. Compositions of nano-particulate naproxen obtained
Figure imgf000011_0001
Para el cálculo de la concentración final en peso de cada uno de los elementos en la composición se empleó la densidad reportada en la literatura como cualquier persona medianamente versada en la materia comprendería. Los datos utilizados fueron los siguientes: For the calculation of the final concentration by weight of each of the elements in the composition, the density reported in the literature was used, as any person moderately versed in the matter would understand. The data used were the following:
Tabla 2. Densidades reportadas en la literatura
Figure imgf000011_0002
Extracto de moringa 0,881- 0,920
Figure imgf000012_0001
Table 2. Densities reported in the literature.
Figure imgf000011_0002
Moringa extract 0.881- 0.920
Figure imgf000012_0001
Ejemplo 2. Método de elaboración Example 2. Preparation method
Para la elaboración de las composiciones del Ejemplo 1 realizaron las siguientes etapas: For the preparation of the compositions of Example 1, the following steps were carried out:
• Moler 2,0 g de naproxeno en polvo en un molino Micro Mili a temperatura ambiente hasta un tamaño de partícula de 200 a 300 nm • Grind 2.0 g of naproxen powder in a Micro Mill at room temperature to a particle size of 200 to 300 nm.
• Suspender el polvo resultante en 10,0 mL de aceite de eucalipto o de cedro con agitación continua de baja revolución (30 a 50 rpm) • Suspend the resulting powder in 10.0 mL of eucalyptus or cedarwood oil with continuous stirring at low revolution (30 to 50 rpm).
• Mezclar hasta que la mezcla esté visiblemente sin agregados • Mix until mixture is visibly free of aggregates.
• Agregar entre 2,0 y 5,0 mL de un aceite aromático, o mezclas de los mismos• Add between 2.0 and 5.0 mL of an aromatic oil, or mixtures thereof
• Adicionar 30 g de gel de petrolato • Add 30 g of petrolatum gel
• Mezclar todos los componentes por aproximadamente 15 a 30 minutos hasta que todos los agregados desaparezcan visiblemente • Mix all components for approximately 15 to 30 minutes until all aggregates visibly disappear.
En el caso de la composición C, se preparó un extracto de moringa calentando el polvo de extracto de hoja de moringa a ebullición en agua con 10% de glicerina, seguido de resuspensión en varios porcentajes de orgánicos/agua, y remoción de los orgánicos mediante lavados consecutivos en agua. Los extractos se filtraron con papel de filtro Whatman No. 10, seguidos de secado a temperatura ambiente y dispersando este precipitado en 2,0 mL de aceite mineral. In the case of composition C, a moringa extract was prepared by heating the moringa leaf extract powder to boiling in water with 10% glycerin, followed by resuspension in various percentages of organics/water, and removal of the organics by consecutive washes in water. The extracts were filtered through Whatman No. 10 filter paper, followed by drying at room temperature and dispersing this precipitate in 2.0 mL of mineral oil.
Ejemplo 3. Efecto de la composición como agente analgésico y antinflamatorio Example 3. Effect of the composition as an analgesic and anti-inflammatory agent
Las composiciones del Ejemplo 1 en un estudio de percepción del dolor dieron como resultado una disminución de la percepción del dolor en una escala subjetiva de 10 puntos de entre 10 y 7 puntos, en donde 10 puntos corresponde a la calificación del dolor inicial. El efecto se observó en un tiempo desde 30 minutos hasta 2 horas después de la aplicación de la composición. The compositions of Example 1 in a pain perception study resulted in a decrease in pain perception on a subjective 10 point scale of between 10 and 7 points, where 10 points corresponds to the initial pain rating. The effect was observed at a time from 30 minutes to 2 hours after the application of the composition.

Claims

REIVINDICACIONES
1. Una composición tópica que comprende: un ingrediente activo que comprende naproxeno nano-particulado; un vehículo oleoso que se selecciona de uno o más aceites ricos en terpenoides, y excipientes farmacéuticamente aceptables. Claims 1. A topical composition comprising: an active ingredient comprising nano-particulate naproxen; an oily carrier selected from one or more terpenoid-rich oils, and pharmaceutically acceptable excipients.
2. La composición según la Reivindicación 1, que comprende adicionalmente quercetina, isoquercetina, ácido clorogénico, astragalina o mezclas de los mismos. 2. The composition according to Claim 1, further comprising quercetin, isoquercetin, chlorogenic acid, astragalin, or mixtures thereof.
3. La composición según la Reivindicación 1, en donde el aceite rico en terpenoides se selecciona entre aceite de eucalipto, aceite de moringa, aceite de té, aceite de salvia, aceite de árboles cítricos, aceite de pino, aceite de cedro, aceite de lavanda, aceite de mentol, y/o aceite de alcanfor. 3. The composition according to Claim 1, wherein the terpenoid-rich oil is selected from eucalyptus oil, moringa oil, tea oil, sage oil, citrus tree oil, pine oil, cedarwood oil, lavender, menthol oil, and/or camphor oil.
4. La composición según la Reivindicación 1, en donde la concentración de naproxeno nano-particulado es entre 0,5 y 15% en peso. 4. The composition according to Claim 1, wherein the concentration of nano-particulate naproxen is between 0.5 and 15% by weight.
5. La composición según la Reivindicación 2, en donde la quercetina, isoquercetina, ácido clorogénico, astragalina o mezclas de los mismos están en una concentración entre 0,1 y 15% en peso. 5. The composition according to Claim 2, wherein the quercetin, isoquercetin, chlorogenic acid, astragalin or mixtures thereof are in a concentration between 0.1 and 15% by weight.
6. La composición según la Reivindicación 1, en donde el excipiente farmacéuticamente aceptable se selecciona del grupo que comprende petrolato, tomillo, aceite de cedro, aceite de limón, aceite de alcanfor, parafina blanda blanca, polioxilglicéridos de caprilocaproilo, aceite de coco, base de dietileno, éter de monoetilenglicol, lanolina, lanolina hidrogenada, alcoholes de lanolina, polioxiglicéridos de lauroil, polioxiglicéridos de linoleolilo, petrolato hidrofílico, petrolato blanco, polideceno hidrogenado, polietilenglicol, polietilenglicol 3350, polietilenglicol monometil éter, poligliceril-3 diisoestearato, succinato de polietilenglicol y vitamina E. 6. The composition according to Claim 1, wherein the pharmaceutically acceptable excipient is selected from the group comprising petrolatum, thyme, cedarwood oil, lemon oil, camphor oil, white soft paraffin, caprylocaproyl polyoxylglycerides, coconut oil, base diethylene, monoethylene glycol ether, lanolin, hydrogenated lanolin, lanolin alcohols, polyoxyglycerides lauroyl, polyoxyglycerides linoleolyl, hydrophilic petrolatum, white petrolatum, hydrogenated polydecene, polyethylene glycol, polyethylene glycol 3350, polyethylene glycol monomethyl ether, polyglyceryl-3 diisostearate, polyethylene glycol succinate and vitamin E.
7. La composición según la Reivindicación 6, en donde la composición está en forma de ungüento. 7. The composition according to Claim 6, wherein the composition is in the form of an ointment.
8. Un método para elaborar una composición de naproxeno nano-particulado, que comprende: a) obtener nano partículas de naproxeno con un tamaño entre 200 y 300 nm; b) mezclar las nano partículas de la etapa a) con uno o más aceites vegetales ricos en terpenoides; c) agregar a la mezcla de la etapa b) excipientes farmacéuticamente aceptables; en donde en la etapa b) se pueden incorporar adicionalmente quercetina, isoquercetina, ácido clorogénico, astragalina o mezclas de los mismos. 8. A method for preparing a nanoparticulate naproxen composition, comprising: a) obtaining nanoparticles of naproxen with a size between 200 and 300 nm; b) mixing the nanoparticles of step a) with one or more vegetable oils rich in terpenoids; c) adding to the mixture of step b) pharmaceutically acceptable excipients; where in step b) quercetin, isoquercetin, chlorogenic acid, astragalin or mixtures thereof can be additionally incorporated.
9. Uso de la composición según cualquiera de las Reivindicaciones 1 a 7 como agente analgésico y/o antinflamatorio. 9. Use of the composition according to any of Claims 1 to 7 as an analgesic and/or anti-inflammatory agent.
10. Un método para el tratamiento de una condición o enfermedad asociada con la inflamación y/o el dolor articular o muscular, que comprende administrar en el sitio del dolor o la inflamación, una cantidad terapéuticamente efectiva de la composición según cualquiera de las Reivindicaciones 1 a 7. 10. A method for treating a condition or disease associated with joint or muscle inflammation and/or pain, comprising administering to the site of pain or inflammation, a therapeutically effective amount of the composition according to any of Claims 1 to 7.
11. El método según la Reivindicación 10, en donde la condición o enfermedad asociada con la inflamación y/o el dolor se selecciona entre artritis reumatoide, osteoartritis, dolor de espalda, dolores crónicos, dolores musculares, dolores musculares asociados con la menstruación, tendinitis, dolor dental y bursitis. 11. The method according to Claim 10, wherein the condition or disease associated with inflammation and/or pain is selected from rheumatoid arthritis, osteoarthritis, back pain, chronic pain, muscle pain, muscle pain associated with menstruation, tendinitis , dental pain and bursitis.
PCT/IB2022/053490 2021-04-15 2022-04-13 Nano-particulated naproxen composition in vegetable oil useful for the treatment of inflammation and pain WO2022219567A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CONC2021/0004783 2021-04-15
CONC2021/0004783A CO2021004783A1 (en) 2021-04-15 2021-04-15 Composition of nano-particulate naproxen in vegetable oil useful for the treatment of inflammation and pain

Publications (1)

Publication Number Publication Date
WO2022219567A1 true WO2022219567A1 (en) 2022-10-20

Family

ID=83640527

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2022/053490 WO2022219567A1 (en) 2021-04-15 2022-04-13 Nano-particulated naproxen composition in vegetable oil useful for the treatment of inflammation and pain

Country Status (2)

Country Link
CO (1) CO2021004783A1 (en)
WO (1) WO2022219567A1 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007148116A2 (en) * 2006-06-23 2007-12-27 Aston University Topical pharmaceutical formulations
WO2010066047A1 (en) * 2008-12-10 2010-06-17 Roch Lebel Topical foaming composition and method of application
IN201621029815A (en) * 2016-08-31 2016-09-16 Shripad Abhimanyu PANSARE
US10806790B1 (en) * 2013-11-12 2020-10-20 Scott Shapiro Pain therapy cream with deep tissue delivery system

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007148116A2 (en) * 2006-06-23 2007-12-27 Aston University Topical pharmaceutical formulations
WO2010066047A1 (en) * 2008-12-10 2010-06-17 Roch Lebel Topical foaming composition and method of application
US10806790B1 (en) * 2013-11-12 2020-10-20 Scott Shapiro Pain therapy cream with deep tissue delivery system
IN201621029815A (en) * 2016-08-31 2016-09-16 Shripad Abhimanyu PANSARE

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ABD EMAN, NAMJOSHI SARIKA, MOHAMMED YOUSUF H., ROBERTS MICHAEL S., GRICE JEFFREY E.: "Synergistic Skin Penetration Enhancer and Nanoemulsion Formulations Promote the Human Epidermal Permeation of Caffeine and Naproxen", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 105, no. 1, 2016, US , pages 212 - 220, XP009540681, ISSN: 0022-3549, DOI: 10.1002/jps.24699 *
ABDULLAH GHASSAN, ABDULKARIM MUTHANNA, SALMAN IBRAHEEM, AMEER O Z, YAM M F, MUTEE, CHITNENI, MAHDI ELRASHID SALEH, BASRI, SATTAR M: "In vitro permeation and in vivo anti-inflammatory and analgesic properties of nanoscaled emulsions containing ibuprofen for topical delivery", INTERNATIONAL JOURNAL OF NANOMEDICINE, vol. 6, 2011, pages 387 - 396, XP055982573, DOI: 10.2147/IJN.S14667 *
ANONYMOUS: "Ultrabengue Gel", PLM, 23 April 2018 (2018-04-23), pages 1 - 2, XP055982571, Retrieved from the Internet <URL:https://www.medicamentosplm.com/Home/productos/ultrabengue_gel/63/101/12401/66> [retrieved on 20220722] *
DAS, ASHA ET AL.: "Natural permeation enhancer for transdermal drug delivery system and permeation evaluation: A review", ASIAN JOURNAL OF PHARMACEUTICAL AND CLINICAL RESEARCH, vol. 10, no. 9, September 2017 (2017-09-01), pages 5 - 9, XP055723474, DOI: http-//dx.doi.org/l 0.221 59/ajpcr.201 7.v1Oi9.19389 *
JAIN VIKAS, THAKUR MONIKA: "Development and characterization naproxen gel bearing eucalyptus oil for topical delivery", APPLIED MEDICAL RESEARCH, vol. 1, no. 2, 2015, pages 48 - 52, XP055982558, DOI: 10.5455/amr. 20150308 022937 *

Also Published As

Publication number Publication date
CO2021004783A1 (en) 2022-10-21

Similar Documents

Publication Publication Date Title
JP2023109849A (en) Dilutable formulations of cannabinoids and processes for their preparation
Pardeike et al. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products
ES2602107T3 (en) Nanoemulsion
Abolmaali et al. Pharmaceutical Nanoemulsions and Their Potential Topical and Transdermal Applications: Pharmaceutical nanoemulsions potential applications
ES2296218T5 (en) COMPOSITION OF REVERSE EMULSION TYPE CONTAINING CALCITRIOL AND 17-CLOBETASOL PROPIONATE AND ITS USE IN COSMETICS AND DERMATOLOGY.
BR112019006081B1 (en) PROCESS FOR EXTRACTING A CANNABINOID FROM A PLANT SOURCE, EXTRACTION MEDIA FOR SELECTIVE EXTRACTION OF A CANNABINOID FROM A PLANT SOURCE CONTAINING CANNABINOID, MEDIUM LOADED WITH CANNABINOID, FOOD, DIETARY SUPPLEMENT OR NUTRACEUTICAL COMPOSITIONS AND PHARMACEUTICAL COMPOSITION
Amol et al. NOVEL DRUG DELIVERY SYSTEM IN HERBAL'S.
US20060241175A1 (en) Vehicle for topical delivery of anti-inflammatory compounds
JP2009545587A (en) Nanoliposomes using esterified lecithin, method for producing the same, and composition for preventing or treating skin diseases comprising the same
Vanti Recent strategies in nanodelivery systems for natural products: A review
Lai et al. Nanocrystals as effective delivery systems of poorly water-soluble natural molecules
Nanavati Phytosome: a novel approach to enhance the bioavailability of phytoconstituent
BRPI0804172A2 (en) chemical compounds formed from nanocapsulations and element complexation
WO2022219567A1 (en) Nano-particulated naproxen composition in vegetable oil useful for the treatment of inflammation and pain
Kalita et al. Resveratrol-phospholipid complexes (phytosomes) with improved physicochemical properties favorable for drug delivery via skin
EP3795146B1 (en) Pain-relieving and anti-inflammatory composition for local use
PT2011504E (en) Skin cream for treatment and/or cleaning of skin for neurodermitis
Ruiz et al. Skin creams made with olive oil
Fatima et al. A review on potential of novel vesicular carriers for carrying herbal drugs in the treatment of dermatological disorders
Janani et al. Perspective chapter: Microemulsion as a game changer to conquer cancer with an emphasis on herbal compounds
Pulipaka et al. A Review on Nano Drug Delivery Systems of Herbal Medicine
Zakharova et al. Supramolecular Strategy for the Design of Nanocarriers for Drugs and Natural Bioactives: Current State of the Art (A Review)
US20230255900A1 (en) Compositions for topical treatment of radiation dermatitis
US20230330019A1 (en) Emulsion formulations of poorly water-soluble compounds
RAWAS DEVELOPMENT AND OPTIMIZATION OF A TOPICAL NANOEMULSION FORMULATIONFORWOUND HEALING

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22787743

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22787743

Country of ref document: EP

Kind code of ref document: A1